NEW YORK (GenomeWeb News) – Prodesse has licensed Invitrogen’s LUX PCR reagents for use in molecular diagnostics, the companies said on Friday.
The agreement marks the first use of the LUX (Light Upon eXtension) PCR chemistries in diagnostic assays, the companies said.
Invitrogen said that the LUX reagents can be used in gene expression studies, biomarker analysis, and functional genomics experiments and enable users to examine multiple targets in one experiment.
Tom Shannon, president and CEO of Prodesse, said in a statement that the technology offers “significant design flexibility as well the tremendous advantage of conveying service rights that do not carry royalty burdens to end users."
Prodesse, based in Waukesha, Wis., develops analyte specific reagents used by CLIA-certified laboratories for detecting infectious disease pathogens. The company currently offers a range of products covering 33 organisms.